RxDoctor Payments Data

Peter Tran, MD

Infectious Disease · Montgomery, OHNPI 1508228859

Payments from drug & device makers

$5,030in general payments, 2019–2025

Across 279 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$992
  • Gilead$969
  • Paratek Pharmaceuticals, Inc.$756
  • AbbVie$673
  • Insmed, Inc.$438
  • Melinta Therapeutics, LLC$348
  • plus $853 from 12 others

What the payments were for

  • Food & beverage$4,89997%
  • Education$1313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,030 in reported general payments places this provider in the 75th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$113,199
Medicare patients
282
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala70$289,375
DovatoDolutegravir Sodium/Lamivudine31$87,451
Daptomycin61$16,377
ErtapenemErtapenem Sodium23$11,074
Fosfomycin Tromethamine34$8,898
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam61$8,548
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod37$4,652
Doxycycline Hyclate136$3,346
Trimethoprim55$2,688
Vancomycin Hcl28$2,569
CeftriaxoneCeftriaxone Sodium35$2,183
Cefazolin Sodium15$1,993
Cefepime Hcl15$1,944
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav55$1,927
Cefdinir33$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$969$289,37570 claims
Viiv Healthcare CompanyDovato$992$87,45131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Montgomery

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →